TY - JOUR
T1 - Behavioural and neuropharmacological properties of the dibenzazepines, desipramine and lofepramine
T2 - studies on the olfactory bulbectomized rat model of depression
AU - O'Connor, William T.
AU - Leonard, Brian E.
PY - 1988
Y1 - 1988
N2 - O'Connor, William T. and Brian E. Leonard: Behavioural and Neuropharmacological Properties of the Dibenzazepines, Desipramine and Lofepramine: Studies on the Olfactory Bulbectomized Rat Model of Depression. Prog. Neuro-Psychopharmacol. & Biol. Psychiat. 1988, 12: 41-51. 1. 1. Lofepramine was compared with its major desipramine for its effects on adaptation to novel objects in the home cage (neophobia) and exploratory behaviours in both sham operated and olfactory bulbectomized rats. 2. 2. In the test for neophobia (marble burying), the aversive response of bulbecotmized rats differed from that of the sham operated animals, the bulbectomized rats showing a diminished aversive response. This response was unaffected by either antidepressant. 3. 3. Of two tests for exploratory activity, the "open field" test clearly differentiated the bulbectomized rats treated with desipramine from those treated with lofepramine. In the lower doses used (1 and 10 mg/kg), only desipramine treatment significantly attenuated the hypermotility of the bulbectomized rats. In high doses (30 mg/kg), lofepramine also attenuated the hypermotility of the bulbectomized rats; this could have been due to the presence of high concentrations of the desipramine metabolite. In a nonstressful novel environment ('hole board'), neither drug significantly affected the behaviour of sham operated or olfactory bulbectomized rats. Neither antidepressant had noticeable anticholinergic properties as indicated by the number of faecal boli deposited. 4. 4. Acute clonidine administration was found to attenuate the activity of rats in the 'open field' apparatus. This effect was attenuated following the chronic administration of desipramine but not lofepramine. It may be concluded that the pharmacological activity of lofepramine is independent of its metabolism to desipramine in vivo.
AB - O'Connor, William T. and Brian E. Leonard: Behavioural and Neuropharmacological Properties of the Dibenzazepines, Desipramine and Lofepramine: Studies on the Olfactory Bulbectomized Rat Model of Depression. Prog. Neuro-Psychopharmacol. & Biol. Psychiat. 1988, 12: 41-51. 1. 1. Lofepramine was compared with its major desipramine for its effects on adaptation to novel objects in the home cage (neophobia) and exploratory behaviours in both sham operated and olfactory bulbectomized rats. 2. 2. In the test for neophobia (marble burying), the aversive response of bulbecotmized rats differed from that of the sham operated animals, the bulbectomized rats showing a diminished aversive response. This response was unaffected by either antidepressant. 3. 3. Of two tests for exploratory activity, the "open field" test clearly differentiated the bulbectomized rats treated with desipramine from those treated with lofepramine. In the lower doses used (1 and 10 mg/kg), only desipramine treatment significantly attenuated the hypermotility of the bulbectomized rats. In high doses (30 mg/kg), lofepramine also attenuated the hypermotility of the bulbectomized rats; this could have been due to the presence of high concentrations of the desipramine metabolite. In a nonstressful novel environment ('hole board'), neither drug significantly affected the behaviour of sham operated or olfactory bulbectomized rats. Neither antidepressant had noticeable anticholinergic properties as indicated by the number of faecal boli deposited. 4. 4. Acute clonidine administration was found to attenuate the activity of rats in the 'open field' apparatus. This effect was attenuated following the chronic administration of desipramine but not lofepramine. It may be concluded that the pharmacological activity of lofepramine is independent of its metabolism to desipramine in vivo.
KW - desipramine
KW - exploratory behaviour
KW - lofepramine
KW - olfactory bulbectomized rat
UR - http://www.scopus.com/inward/record.url?scp=0023930166&partnerID=8YFLogxK
U2 - 10.1016/0278-5846(88)90060-7
DO - 10.1016/0278-5846(88)90060-7
M3 - Article
C2 - 3363165
AN - SCOPUS:0023930166
SN - 0278-5846
VL - 12
SP - 41
EP - 51
JO - Progress in Neuro-Psychopharmacology and Biological Psychiatry
JF - Progress in Neuro-Psychopharmacology and Biological Psychiatry
IS - 1
ER -